Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Richard A. Larson, MD, Brian J. Druker, MD, Francois Guilhot, MD, Stephen G. O’Brien, MBChB, PhD, Insa Gathmann, MS, Gilles J. Riviere, PhD, Charlene So, PharmD, Yanfeng Wang, PhD, on Behalf of the IRIS Study Group

Blood (2006) 108 (11): 429.

https://doi.org/10.1182/blood.V108.11.429.429

Published: 2006

Journal Articles

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Jaspal Kaeda, Andreas Hochhaus, Jerald Radich, Susan Branford, Charlene So, Insa Gathmann, Elisabeth Wehrle, John Goldman, Timothy Hughes, on Behalf of IRIS Study Group

Blood (2006) 108 (11): 2139.

https://doi.org/10.1182/blood.V108.11.2139.2139

Published: 2006

Journal Articles

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke, Agnès Guerci-Bresler, Brian J. Druker, Richard A. Larson, Steve O'Brien, Charlene So, Giorgio Massimini, François Guilhot

Blood (2006) 108 (5): 1478–1484.

https://doi.org/10.1182/blood-2006-02-001495

Published: 2006

Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD

Blood (2005) 106 (11): 165.

https://doi.org/10.1182/blood.V106.11.165.165

Published: 2005

Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD

Blood (2005) 106 (11): 163.

https://doi.org/10.1182/blood.V106.11.163.163

Published: 2005

Journal Articles

Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.

Michael W. Deininger, MD, PhD, Hagop M. Kantarjian, MD, Park Byung, Andreas Hochhaus, MD, Charles L. Sawyers, MD, Michele Baccarani, MD, Insa Gathmann, Charlene So, Brian J. Druker, MD, Francois Guilhot, MD

Blood (2005) 106 (11): 1082.

https://doi.org/10.1182/blood.V106.11.1082.1082

Published: 2005

NARROW

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.

Email alerts

ASH Publications

American Society of Hematology

Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data.

Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2 nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1 st Line IM Patients.

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only